64th ASH Annual Meeting and Exposition: 703. Cellular Immunotherapies: Basic and Translational III

Symposia: Cellular Immunotherapies: Basic and Translational Oral and Poster Abstracts
Oral

Research, ALL, Lymphoid Leukemias, Biological therapies, Fundamental Science, Translational Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, T Cell lymphoma, Diseases, Gene Therapy, Immune Disorders, immunodeficiency, Therapies, Immunotherapy, Lymphoid Malignancies, Adverse Events, metabolism, Biological Processes, Natural Killer (NK) Cell Therapies, Technology and Procedures, gene editing, Transplantation

La Nouvelle Orleans Ballroom C (Ernest N. Morial Convention Center)

Moderators:

Melody Smith, MD, MS, Memorial Sloan-Kettering Cancer Center and Stephan Mielke, MD, Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center

Disclosures:

Mielke: DNA Prime SA: Other: via my institution, Speakers Bureau; Miltenyi: Other: DSMB via my institution; Immunicum/Mendus: Other: DSMB via my institution; KITE/GILEAD: Other: Expert Panel with travel costs; via my institution; Novartis: Other: via my institution, Speakers Bureau; Celgene/BMS: Other: via my institution, Speakers Bureau; Janssen: Other: via my institution, Speakers Bureau; SWECARNET: Membership on an entity's Board of Directors or advisory committees, Other: via my institution.

This session focuses on future CAR T cell therapies at their early stage of translational development but with a clear link to the clinic such as unmet medical need (for example in T-ALL). Focus is on the improvement of CAR T cell therapy by increasing fitness and persistence as well as enhancing anti-tumor effects of gene-modified effector cells in animal models. This contains novel mechanistic insights in antigen-engagement and the role of co-stimulation and even mitochondria and opens new fascinating perspectives such as the use of regulatory CAR T cells and advanced off-the shelf treatment strategies.

4:30 PM

483

Interleukin 18 Suppresses Regeneration of the Thymus

David Granadier, BS¹^*, Kirsten Cooper²^*, Sinéad Kinsella, MSc, PhD¹, Cindy Evandy³^*, Lorenzo Iovino, MD, PhD⁴, Paul DeRoos²^*, Steve Shannon-Sevillano¹^*, Dante Denny Acenas, BS¹^* and Jarrod A Dudakov, PhD²

¹Fred Hutchinson Cancer Research Center, Seattle, WA
²Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
³Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Hematology Division, AOUP, Seattle, WA

4:45 PM

974

Intercellular Mitochondrial Transfer Enhances Metabolic Fitness and Anti-Tumor Effects of CAR T Cells

Shinpei Harada¹^*, Daigo Hashimoto, MD², Hajime Senjo, M.D.², Kazuki Yoneda, M.D.²^*, Zixuan Zhang²^*, Xuanzhong Chen²^*, Ryo Kikuchi, M.D.²^*, Masahiro Chiba, M.D.²^*, Hiroyuki Ohigashi, M.D., Ph.D.²^*, Takahide Ara, M.D., Ph.D.²^*, Masao Nakagawa, M.D., Ph.D.², Masashi Suganuma, M.D., Ph.D.³^*, Rick C. Tsai, M.D., D.M.D.³^* and Takanori Teshima, M.D., Ph.D.²

¹Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo City, Japan
²Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
³LUCA Science Inc., Tokyo, Japan

5:00 PM

975

Development of an Off-the-Shelf Chimeric Antigen Receptor (CAR)-T Cell Therapy for T-Cell Acute Lymphoblastic Leukemia (T-ALL) without Gene Editing

Xing Fah Alex Wong¹^*, Josie Ng¹^*, Simin Zheng¹^*, Rizal Ismail¹^*, Hongliang Qian¹^*, Dario Campana² and Ying Xim Tan³

¹MediSix Therapeutics, Singapore, Singapore
²Department of Pediatrics and Cancer Science Institute, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
³Medisix Therapeutics, Singapore, Singapore

5:15 PM

976

Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells

Anthony M Battram, PhD^1,2^*, Aina Oliver-Caldes, MD^2,3^*, Miquel Bosch i Crespo^2,3^*, Oriol Cardus, MSc^2,3^*, David F. Moreno, MD^2,3^*, Luis Gerardo Rodríguez-Lobato, MD, PhD^2,3^*, Alvaro Urbano-Ispizua, MD, PhD^2,4,5,6 and Carlos Fernandez de Larrea, MD^2,3,5

¹Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain
²Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
³Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain
⁴Institut Clinic de Malalties Hematologiques i Oncologiques (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain
⁵Department of Hematology, University of Barcelona, Barcelona, Spain
⁶Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain

5:30 PM

977

CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy

Reona Leo Sakemura, MD, PhD^1,2, Claudia Manriquez-Roman^1,2,3,4, Paulina Horvei, M.D.¹^*, Michelle J. Cox, Ph.D.¹, Truc Huynh¹^*, James H. Girsch^1,2,3,4^*, Olivia Sirpilla, BS^1,2,3,5, Kun Yun^1,2,3,4, Carli M. Stewart, BS^1,2,3,5, Ismail Can, PhD^1,2,3,6, Ekene J. Ogbodo, Ph.D.^1,2^*, Mohamad M. Adada, M.D., Ph.D.^1,2, Lionel A. Kankeu Fonkoua, M.D.^1,2,7, Mehrdad Hefazi, M.D.^1,2, Michael W. Ruff, M.D.^1,8^*, Kristina Ilieva-Babinski⁹^*, Christian Augsberger⁹^*, Maria Patra-Kneuer, Ph.D.⁹^*, Christina Heitmüller, Ph.D.⁹^*, Stefan Steidl, Ph.D.⁹^*, Sameer A. Parikh, MD¹⁰, Wei Ding, MBBS, PhD², Neil E. Kay, MD¹⁰, Grzegorz S. Nowakowski, MD², Elizabeth L. Siegler, Ph.D.^1,2^* and Saad S. Kenderian, MD^1,2,4,11

¹T Cell Engineering, Mayo Clinic, Rochester, MN
²Division of Hematology, Mayo Clinic, Rochester, MN
³Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN
⁴Department of Molecular Medicine, Mayo Clinic, Rochester, MN
⁵Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN
⁶Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN
⁷Department of Oncology, Mayo Clinic, Rochester, MN
⁸Department of Neurology, Mayo Clinic, Rochester, MN
⁹MorphoSys AG, Planegg, Germany
¹⁰Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
¹¹Department of Immunology, Mayo Clinic, Rochester, MN

5:45 PM

978

iPSC-Derived HLA-A2 CAR Tregs Showed Suppression of GvHD in a Xenograft Model

Hisashi Yano, MD^1,2,3,4^*, Takayuki Sato, PhD^2,5^*, Tokuyuki Shinohara, PhD^2,5^*, Keiko Koga, PhD^2,5^*, Shoichi Iriguchi, PhD^2,3^*, Atsushi Matsuda, PhD^2,5^*, Yasuyuki Miyake^2,3^*, Yoshiaki Kassai, PhD^2,5^*, Hitoshi Kiyoi⁴ and Shin Kaneko, MD, PhD^2,3^*

¹Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya-Shi, Japan
²Immune cell therapy project, Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa-shi, Japan
³Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto-shi, Japan
⁴Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya-shi, Japan
⁵T-CiRA discovery, Takeda Pharmaceutical Company Limited, Fujisawa-shi, Japan

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703A.O1.6 703. Cellular Immunotherapies: Basic and Translational III